Skip to content
DataLookout
Menu

NCT06089382

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Recurrence-Free Survival (RFS)
Timeframe: Randomization up to approximately 36 months

Secondary (5)

RFS Rate at 12 and 24 Months
Overall Survival (OS)
Adverse events (AEs)
Quality of Life (QoL) Scale Score
Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score

Arms and interventions

Sintilimab Plus LenvatinibExperimental
TACE(one cycle) + active surveillanceActive comparator

Drugs: Sintilimab, Lenvatinib

Procedures: Transarterial Chemoembolization (TACE)

Sites

1 site in 1 country

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China